Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and immunogenicity of two vaccinations of Ad26.RSV.preF given one year apart in adults aged 60 and older; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 1 | Status: COMPLETED